Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The market performance for the Chinese medicine sector showed a slight decline of 1.67% last week, which is relatively smaller compared to other pharmaceutical segments [1]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is reported at 26.63X, with a slight decrease of 0.45X week-on-week, indicating a valuation within the historical range [2]. - The demand for tonic herbs continues to grow, leading to a slight increase in the Chinese medicinal herb price index, which rose by 0.1% last week [3]. - The integration of Chinese medicinal pieces into a national drug traceability code system is accelerating, which is expected to enhance the quality and management of the industry [4]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6234.32 points, down 1.67% last week, while the overall pharmaceutical sector index fell by 2.06% [1][11]. - Notable companies with strong performance include Wanbangde, Tianmu Pharmaceutical, and Guhang Medicine, while underperformers include *ST Changyao and ST Hulahua [1][17]. Valuation - The current PE ratio for the Chinese medicine sector is 26.63X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [2]. - The price-to-book (PB) ratio stands at 2.24X, with a year-to-date maximum of 2.52X and a minimum of 2.17X [2]. Industry Trends - The demand for tonic herbs is on the rise, contributing to a slight increase in the price index for Chinese medicinal herbs [3]. - The national drug traceability system for Chinese medicinal pieces is being implemented, which is expected to improve the quality and traceability of medicinal materials [4]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [5]. - Specific investment targets include companies with strong R&D capabilities, unique products, and those less affected by price reductions due to centralized procurement [9].

Investment Rating - The report maintains a "Buy" rating for the machinery industry [2][7]. Core Insights - The December PMI for general equipment returned to the expansion zone at 50.1%, up 0.9 percentage points from the previous month, marking the first return to expansion since April of the previous year. Key sub-indices such as production, new orders, new export orders, and backlog orders also showed improvements [4]. - The domestic humanoid robot shipment is expected to exceed 18,000 units in 2025, representing a growth of over 650% compared to 2,400 units in 2024. Major companies in this sector include Zhiyuan Robotics and Yusu Technology [5]. - The report suggests that the recovery of manufacturing demand will continue to drive the overall demand for upstream general equipment, supported by ongoing macroeconomic policies and the upcoming Spring Festival inventory preparations [6][7]. Summary by Sections Industry Performance - Over the past 12 months, the machinery industry has shown a relative return of 27.5% and an absolute return of 50.2% [3]. - In the last week, the machinery sector rose by 1.3%, with the robotics segment leading at 5.2% [9]. Key Companies and Predictions - The report includes earnings forecasts and ratings for key companies, with several companies such as Huichuan Technology and Sany Heavy Industry receiving a "Buy" rating [21]. - Notable companies with significant stock performance include Buke Co., which saw a weekly increase of 50.4% [16]. Market Trends - The report highlights the positive impact of government policies on manufacturing recovery, with expectations for continued improvement in profitability and manufacturing sentiment in 2026 [6][7]. - The machinery industry's current PE (TTM) is 39.3 times, indicating a high valuation compared to historical levels [14].

证券研究报告 2026 年 1 月 4 日 湘财证券研究所 相关研究： | 1.《近期板块走强，关注零售百货 | | --- | | 业态变革》 2024.12.11 | | 2.《2024年社零总额增长3.5%，线 | | 下商超业态平稳复苏》2025.01.24 | 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 0.0 5.7 -10.4 绝对收益 0.0 5.5 12.3 -50.00% 0.00% 50.00% 沪深300 商贸零售(申万) 注：相对收益与沪深 300 相比 分析师：聂孟依 证书编号：S0500524040001 Tel：(8621) 50299667 Email：nmy06967@xcsc.com 地址：上海市浦东新区银城路 88 号 中国人寿金融中心 10 楼 行业研究 商贸零售行业周报 元旦假期文旅消费数据出炉，关注相关零售产业链 核心要点： ❑ 商贸零售板块上周下跌 1.63% 根据 wind，上周，商贸零售报收 2422.59 点，下跌 1.63%，涨幅排名位列 申万一级行业第26位，跑输沪深300指数1.04个百分点；贸易Ⅱ报收4 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - The vaccine industry is experiencing steady growth, with 68 preventive vaccines approved for clinical trials in 2025, an increase of 13 from 2024 [3] - The industry is transitioning from scale expansion to innovation-driven growth, facing short-term challenges due to supply-demand imbalances and homogenized competition, but the long-term outlook remains positive [9][24] - Key drivers for the industry's development include policy support, increasing demand due to aging populations, and technological innovation [9][26] Summary by Sections Industry Dynamics - The approval of new vaccines is on the rise, with significant advancements in innovative vaccines and multi-valent products [3] - The market is characterized by a high proportion of Me-too products, leading to intense competition and price declines [8] Market Performance - The vaccine sector has seen a cumulative decline of 12.35% since the beginning of 2025, with a recent weekly drop of 2.52% [4][14] - Companies such as Olin Bio, Hualan Biological, and CanSino have shown better performance, while companies like Gendik and Wantai Biologics have lagged [5] Valuation Metrics - The vaccine sector's PE (ttm) is 90.01X, down 2.34X from the previous period, while the PB (lf) stands at 1.74X, reflecting a slight decrease [6] Investment Recommendations - The industry is advised to focus on companies with strong R&D capabilities and differentiated product lines, particularly those with high technical barriers [9][26] - Companies like CanSino and Kanghua Biological are recommended due to their innovative strengths and market demand resilience [9][26]

Investment Rating - The industry rating is maintained at "Overweight" [9][39]. Core Insights - The financial stability report indicates that the asset quality of banks continues to consolidate, with significant progress in resolving debt risks associated with financing platforms and managing risks in small and medium-sized financial institutions [8][36]. - As of the end of 2024, approximately 40% of financing platforms have exited the platform sequence through market-oriented transformations, with the scale of operational financial debt for these platforms around 14.8 trillion yuan, a decrease of about 25% from early 2023 [9][36]. - The average interest rate for newly issued bonds by financing platforms dropped to 2.67% in Q4 2024, a reduction of over 2 percentage points compared to Q1 2023, indicating a significant decrease in financing risk premiums [9][36]. - The overall risk status of national banks is stable, with 71% of the asset scale concentrated in 21 national banks, and the majority of ratings falling within levels 1-5 [9][36]. - The report highlights that there are no "red zone" banks in nine provinces, and the number of "red zone" banks in 13 provinces remains in single digits, indicating a significant reduction in existing risks across most regions [10][36]. Summary by Sections Market Performance - Over the past 12 months, the industry has shown a relative return of -10.7% and an absolute return of 7.0% [6]. Investment Recommendations - The banking sector's profitability is stabilizing at the bottom, with ongoing risk management in key areas such as urban investment and real estate, creating conditions for valuation recovery [12][39]. - In a low-interest-rate environment, the high dividend advantage of bank stocks is expected to continue, highlighting their investment value [12][39]. - Recommended banks include Industrial and Commercial Bank of China, Bank of China, CITIC Bank, Jiangsu Bank, Shanghai Rural Commercial Bank, Chongqing Rural Commercial Bank, and Suzhou Bank [12][39].

Investment Rating - The report maintains a "Buy" rating for the medical services industry [5][66]. Core Insights - The medical and biological sector experienced a decline of 2.06% this week, ranking 28th among 31 primary industries [1][11]. - The AI pharmaceutical company Insilico Medicine was listed on the Hong Kong Stock Exchange, raising HKD 2.277 billion, marking it as the highest fundraising biotech IPO in 2025 [4][63]. - AI technology is significantly reducing the time and costs associated with drug discovery and clinical trials, with potential savings of approximately USD 26 billion annually in compound screening and clinical trial costs [5][65]. Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.28X, with a PB (lf) of 3.17X, showing a decrease of 0.52X in PE and 0.05X in PB from the previous week [3][30]. - The medical services II sub-industry index closed at 6363.18 points, down 1.40% [22][23]. Company Performance - Top-performing companies in the medical services sector include: - Purui Eye Hospital (+5.3%) - Sanbo Brain Science (+4.7%) - Puris (+3.0%) - Tigermed (+2.9%) - Baicheng Pharmaceutical (+2.2%) - Underperforming companies include: - Bid Pharmaceutical (-6.6%) - Sunshine Nuohua (-6.1%) - Zhaoyan New Drug (-5.2%) - International Medicine (-4.0%) - Kanglong Chemical (-3.5%) [2][28]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing services, with companies like WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics being highlighted [9][66]. - It also recommends looking at third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, with companies like Aier Eye Hospital and Dean Diagnostics [9][66].

Investment Rating - The industry investment rating is maintained as "Buy" [3] Core Insights - Demand remains weak, and policies need to be strengthened to stimulate the market [2] - In major cities, the resilience of second-hand housing transactions is observed, while new housing demand remains weak [5][6] - The central economic work conference emphasizes city-specific policies to control increments, reduce inventory, and optimize supply [8] Summary by Sections Market Performance - Over the past twelve months, the relative performance of the real estate sector compared to the CSI 300 index has decreased by 16% [4] - Absolute returns for the sector are down by 4% over the past month and 9% over the past three months [4] Transaction Data - In Beijing, the average daily transaction of second-hand homes was 702 units (down 8% year-on-year), while new homes saw an average of 159 units (down 31% year-on-year) [5] - In Shanghai, second-hand homes averaged 808 units (down 13% year-on-year), and new homes averaged 340 units (down 31% year-on-year) [6] - In Shenzhen, second-hand homes averaged 154 units (down 21% year-on-year), and new homes averaged 58 units (down 73% year-on-year) [6] Investment Recommendations - The report suggests focusing on leading real estate companies with strong land acquisition capabilities and land reserves in core cities, such as Poly Developments [8] - It also highlights the potential for valuation recovery in leading intermediary firms benefiting from increased second-hand housing transactions, such as I Love My Home [8]

Report Information - Report Title: Fund Market Tracking and ETF Strategy Allocation Monthly Report [2] - Report Date: January 3, 2026 [1] - Analyst: Li Zhengwei [6] 1. Report Industry Investment Rating No industry investment rating information was provided in the report 2. Report Core Views - As of December 31, 2025, the number and total net asset value of funds in the market continued to rise and the growth - oriented funds outperformed the value - oriented funds in December 2025 [4][11] - The scale of the ETF market also expanded in December 2025, with stock - type ETFs having a relatively high overall return rate and cross - border ETFs performing the worst [6][31] - Two ETF rotation strategies were introduced, and both strategies had certain cumulative excess returns since 2023 [8] - Investment suggestions were made for January 2026, recommending specific industries and corresponding ETFs for different strategies [9] 3. Summary by Directory 3.1 Fund Market Tracking - **Market Overview**: As of December 31, 2025, there were 13,617 funds in the market, an increase of 142 from the end of the previous month. The total net asset value of funds was 36.32 trillion yuan, an increase of 315.115 billion yuan. Stock - type funds increased the most in number and scale in December [11][15] - **Fund Performance**: From December 1 to 31, 2025, the growth fund index, balance fund index, and value fund index had returns of 3.69%, 2.71%, and 1.14% respectively. The growth - type fund outperformed the value - type fund. The median return of all funds in December was 0.53%, and the proportion of funds with positive returns was 79.33%. Yongying High - end Equipment Selection A had the highest increase in December, and Yongying Technology Selection A had the highest increase since the beginning of the year [17][22] 3.2 ETF Market Tracking - **ETF Market Composition**: As of December 31, 2025, there were 1,401 ETFs in the Shanghai and Shenzhen stock markets, an increase of 32 from the previous period. The total asset management scale was 6.02 trillion yuan, an increase of 329.581 billion yuan, and the total share was 3.37 trillion shares, an increase of 132.247 billion shares [24] - **ETF New Products**: In December 2025, 18 ETFs were newly listed, including 5 science - innovation and entrepreneurship artificial intelligence ETFs and 13 other stock - type ETFs. 32 ETFs were newly established, with a total issuance scale of 12.536 billion yuan [26] - **ETF Product Classification Performance**: In December, stock - type ETFs had a relatively high overall return rate with a median return of 3.34%, while cross - border ETFs had the worst performance with a median return of - 3.50%. Stock - type ETFs also had the highest internal deviation in December [31] 3.3 ETF Strategy Tracking - **Based on Main Funds' Industry ETF Rotation**: The strategy focused on the banking, food and beverage, and petroleum and petrochemical industries in December 2025. In December 2025, the cumulative return of the strategy was - 1.70%, and the cumulative excess return relative to the CSI 300 index was - 3.98%. Since 2023, the cumulative return of the strategy was 48.47%, and the cumulative excess return relative to the CSI 300 index was 28.88% [8] - **PB - ROE Framework - based Industry ETF Rotation**: The strategy focused on the automobile, beauty care, and agriculture, forestry, animal husbandry and fishery industries in December 2025. In December 2025, the cumulative return of the strategy was - 1.23%, and the cumulative excess return relative to the CSI 300 index was - 3.51%. Since 2023, the cumulative return of the strategy was 25.47%, and the cumulative excess return relative to the CSI 300 index was 5.89% [8] 3.4 Investment Suggestions - For the industry preferences of main funds, in January 2026, the non - ferrous metals, non - banking finance, and steel industries were favored, and the corresponding ETFs were their industry ETFs [9] - According to the industry PB - ROE situation and supplementary indicators, the PB - ROE framework - based ETF rotation strategy recommended paying attention to the communication, agriculture, forestry, animal husbandry and fishery, and transportation industries in January, and the corresponding ETFs were their industry ETFs [9]

Core Insights - The report highlights the ongoing iteration of large model technology, leading to a wave of innovation in AI-enabled consumer electronics, particularly in edge AI deployment, which offers low cost, high performance, and enhanced privacy security [4][20][26]. Group 1: Industry Performance - The electronic industry has shown a relative return of 30.2% over the past 12 months, outperforming the CSI 300 index, with an absolute return of 47.9% [3]. - Traditional consumer electronics have entered a phase of low growth, with smartphone and PC sales stabilizing, while TWS (True Wireless Stereo) devices are also experiencing slow growth [15]. Group 2: Edge AI Development - The development of model compression technology has laid the groundwork for deploying large models on edge devices, enhancing the capabilities of edge AI [21][26]. - Companies like Huawei and ByteDance are showcasing significant applications of edge AI in smartphones, with products like the Doubao mobile assistant demonstrating the potential for complex operations and cross-application functionality [30][32]. Group 3: ASIC Demand - The demand for ASIC (Application-Specific Integrated Circuit) is surging due to its cost-effectiveness and customization advantages over GPUs, with the market expected to grow from $6.6 billion in 2023 to $55 billion by 2028, reflecting a compound annual growth rate (CAGR) of 53% [5][71]. - Major tech companies are increasingly developing their own ASICs, with Google and Amazon leading the way in supplying these chips, further validating their performance and commercial value [9][71]. Group 4: PCB Market Growth - The demand for PCBs (Printed Circuit Boards) is expected to rise as AI companies and global internet giants invest heavily in data center expansions, with a projected CAGR of 21% in global data center capital expenditures by 2029 [6]. - The increasing complexity of AI servers and high-speed switches is driving up the value of individual PCBs, leading to a simultaneous increase in both volume and price [6][68]. Group 5: Investment Recommendations - The report suggests focusing on companies within the edge AI, ASIC, and PCB supply chains, maintaining a bullish outlook on the electronic industry [8][9]. - Specific companies to watch include Rockchip, Hengxuan Technology, and Horizon Robotics in the edge AI sector, and Chipone and Cambrian in the ASIC sector [9].

证券研究报告 2025 年 12 月 31 日 湘财证券研究所 行业研究 银行业年度策略 高股息为盾，静待价值修复 相关研究： 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 | 相对收益 | -4.85 | 4.99 | -10.62 | | --- | --- | --- | --- | | 绝对收益 | -2.10 | 5.22 | 5.69 | 分析师：郭怡萍 证书编号：S0500523080002 Tel：(8621) 50295327 Email：guoyp@xcsc.com 中国人寿金融中心10楼 核心要点： 市场回顾 今年银行板块行情节奏呈现"前强、中弱、后稳"的走势，主要反映从避 险主导到寻求增长的市场风格转换过程，以及资产风险预期的变化。 政策导向：宽松政策过渡期，金融支持实体经济 | 1. | 《2025年中期策略-价值重估仍 | | --- | --- | | 在进行时》 | 2025.07.02 | | 2. | 《业绩底部修复，配置价值提 | | 升》 | 2025.09.05 | 2026 年，政策环境正从此前的超常规逆周期调节模式，向更具稳定性和 ...